A011000 Stock Overview
A biopharmaceutical company, engages in the research, development, and contract manufacturing of nucleic acid-based biopharmaceuticals.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 4/6 |
Dividends | 0/6 |
GeneOne Life Science, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | ₩3,535.00 |
52 Week High | ₩4,735.00 |
52 Week Low | ₩1,996.00 |
Beta | -2.04 |
11 Month Change | 64.42% |
3 Month Change | 54.70% |
1 Year Change | -13.25% |
33 Year Change | -84.63% |
5 Year Change | 37.55% |
Change since IPO | 320.17% |
Recent News & Updates
Recent updates
Shareholder Returns
A011000 | KR Biotechs | KR Market | |
---|---|---|---|
7D | -8.1% | 1.5% | 1.9% |
1Y | -13.3% | 38.5% | 5.0% |
Return vs Industry: A011000 underperformed the KR Biotechs industry which returned 38.5% over the past year.
Return vs Market: A011000 underperformed the KR Market which returned 5% over the past year.
Price Volatility
A011000 volatility | |
---|---|
A011000 Average Weekly Movement | 11.3% |
Biotechs Industry Average Movement | 9.5% |
Market Average Movement | 6.5% |
10% most volatile stocks in KR Market | 12.1% |
10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A011000's share price has been volatile over the past 3 months.
Volatility Over Time: A011000's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1976 | 73 | Young-Keun Park | www.genels.com |
GeneOne Life Science, Inc., a biopharmaceutical company, engages in the research, development, and contract manufacturing of nucleic acid-based biopharmaceuticals. Its small molecule pipeline comprises GLS-1027, which is in Phase I clinical trial for treatment of nephropathy and inflammatory diseases; GLS-1200 that is in Phase II clinical trial to treat Rhinosinusitis; GLS-1027 and GLS-1200, which is Phase II clinical trial for treatment of COVID-19. The company’s nucleic acid vaccines include GLS-3000 mRNA under feasible study and GLS-5310 DNA under phase 2 stage for the treatment of SARS-CoV-2; GLS-5100 under pre-clinical stage for prevention of herpes zoster; and GLS-5140 under pre-clinical stage for the treatment of SFTS prophylaxis.
GeneOne Life Science, Inc. Fundamentals Summary
A011000 fundamental statistics | |
---|---|
Market cap | ₩282.20b |
Earnings (TTM) | -₩73.64b |
Revenue (TTM) | ₩40.80b |
6.9x
P/S Ratio-3.8x
P/E RatioIs A011000 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
A011000 income statement (TTM) | |
---|---|
Revenue | ₩40.80b |
Cost of Revenue | ₩47.39b |
Gross Profit | -₩6.59b |
Other Expenses | ₩67.05b |
Earnings | -₩73.64b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -922.52 |
Gross Margin | -16.15% |
Net Profit Margin | -180.49% |
Debt/Equity Ratio | 13.0% |
How did A011000 perform over the long term?
See historical performance and comparison